Insulet Co. (NASDAQ:PODD) Position Increased by SRS Capital Advisors Inc.

SRS Capital Advisors Inc. increased its stake in Insulet Co. (NASDAQ:PODD) by 43.1% during the 4th quarter, HoldingsChannel reports. The firm owned 186 shares of the medical instruments supplier’s stock after acquiring an additional 56 shares during the period. SRS Capital Advisors Inc.’s holdings in Insulet were worth $49,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also made changes to their positions in PODD. Baillie Gifford & Co. lifted its holdings in shares of Insulet by 20.7% in the 3rd quarter. Baillie Gifford & Co. now owns 2,275,701 shares of the medical instruments supplier’s stock worth $529,669,000 after purchasing an additional 389,639 shares during the last quarter. Mizuho Securities USA LLC lifted its holdings in shares of Insulet by 5,928.1% in the 3rd quarter. Mizuho Securities USA LLC now owns 325,821 shares of the medical instruments supplier’s stock worth $75,835,000 after purchasing an additional 320,416 shares during the last quarter. Alecta Tjanstepension Omsesidigt bought a new stake in shares of Insulet in the 4th quarter worth approximately $53,184,000. Charles Schwab Investment Management Inc. lifted its holdings in shares of Insulet by 43.8% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 636,265 shares of the medical instruments supplier’s stock worth $148,091,000 after purchasing an additional 193,839 shares during the last quarter. Finally, Westfield Capital Management Co. LP raised its stake in Insulet by 27.6% during the 3rd quarter. Westfield Capital Management Co. LP now owns 754,872 shares of the medical instruments supplier’s stock valued at $175,697,000 after acquiring an additional 163,388 shares in the last quarter.

Insider Buying and Selling

In other news, CAO Lauren Budden sold 915 shares of Insulet stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $275.62, for a total transaction of $252,192.30. Following the transaction, the chief accounting officer now owns 5,733 shares in the company, valued at approximately $1,580,129.46. The trade was a 13.76 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Eric Benjamin sold 12,394 shares of Insulet stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $280.00, for a total value of $3,470,320.00. Following the transaction, the executive vice president now owns 11,383 shares in the company, valued at $3,187,240. This represents a 52.13 % decrease in their position. The disclosure for this sale can be found here. Insiders own 0.47% of the company’s stock.

Insulet Stock Performance

Shares of NASDAQ PODD opened at $251.81 on Friday. The company has a quick ratio of 2.80, a current ratio of 3.68 and a debt-to-equity ratio of 1.21. The stock has a market capitalization of $17.68 billion, a price-to-earnings ratio of 43.49, a PEG ratio of 3.62 and a beta of 1.29. The stock’s fifty day simple moving average is $274.36 and its 200 day simple moving average is $251.98. Insulet Co. has a 52-week low of $160.19 and a 52-week high of $289.46.

Insulet (NASDAQ:PODD) last issued its earnings results on Thursday, February 20th. The medical instruments supplier reported $1.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.00 by $0.15. The business had revenue of $597.50 million for the quarter, compared to analysts’ expectations of $582.02 million. Insulet had a return on equity of 24.46% and a net margin of 20.19%. As a group, sell-side analysts forecast that Insulet Co. will post 3.92 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have weighed in on the company. StockNews.com downgraded Insulet from a “buy” rating to a “hold” rating in a research note on Tuesday. Stifel Nicolaus lifted their target price on Insulet from $245.00 to $293.00 and gave the company a “hold” rating in a research note on Friday, February 21st. Canaccord Genuity Group lifted their target price on Insulet from $304.00 to $324.00 and gave the company a “buy” rating in a research note on Friday, February 21st. Morgan Stanley lifted their target price on Insulet from $234.00 to $317.00 and gave the company an “overweight” rating in a research note on Monday, November 11th. Finally, Royal Bank of Canada assumed coverage on Insulet in a research note on Thursday. They set an “outperform” rating and a $340.00 target price on the stock. Four analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. According to MarketBeat, Insulet currently has an average rating of “Moderate Buy” and an average target price of $292.06.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.